Significance of primary lesion resection in Stage IV breast cancer

Tadahiko Shien, Hiroji Iwata

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Primary breast tumor resection is not recommended with metastatic disease due to lack of evidence indicating prognostic benefit. Results from ongoing trials are needed to test tumor resection efficacy.Abstract: Systemic treatment with drugs is administered to prolong survival and palliate symptoms in Stage IV breast cancer patients who have distant metastases at diagnosis. Surgical procedures for the primary tumor are not actively recommended in guidelines due to lack of evidence indicating prognostic benefit. Recently, several retrospective studies have shown primary tumor resection to prolong overall survival in patients with Stage IV breast cancer. Prospective randomized trials began enrolling patients to examine this possibility and two have already reported results. However, the results of these two trials were discordant. The first trial, conducted in India, reported negative effects of primary tumor resection after primary systemic therapy. A Turkish trial then obtained a positive effect of surgery as primary treatment. Several questions regarding the effects, timing, methods and eligibility for primary surgery have yet to be answered. Robust evidence, which is anticipated from other ongoing trials examining surgery for metastatic breast cancer, is eagerly awaited.

Original languageEnglish
Article numberhyx027
Pages (from-to)381-384
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume47
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Breast Neoplasms
Neoplasms
Survival
India
Therapeutics
Retrospective Studies
Guidelines
Neoplasm Metastasis
Pharmaceutical Preparations

Keywords

  • Prognosis
  • Stage IV breast cancer
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Significance of primary lesion resection in Stage IV breast cancer. / Shien, Tadahiko; Iwata, Hiroji.

In: Japanese Journal of Clinical Oncology, Vol. 47, No. 5, hyx027, 01.05.2017, p. 381-384.

Research output: Contribution to journalReview article

@article{86d60bdf87de450da04e04b85fdb36cb,
title = "Significance of primary lesion resection in Stage IV breast cancer",
abstract = "Primary breast tumor resection is not recommended with metastatic disease due to lack of evidence indicating prognostic benefit. Results from ongoing trials are needed to test tumor resection efficacy.Abstract: Systemic treatment with drugs is administered to prolong survival and palliate symptoms in Stage IV breast cancer patients who have distant metastases at diagnosis. Surgical procedures for the primary tumor are not actively recommended in guidelines due to lack of evidence indicating prognostic benefit. Recently, several retrospective studies have shown primary tumor resection to prolong overall survival in patients with Stage IV breast cancer. Prospective randomized trials began enrolling patients to examine this possibility and two have already reported results. However, the results of these two trials were discordant. The first trial, conducted in India, reported negative effects of primary tumor resection after primary systemic therapy. A Turkish trial then obtained a positive effect of surgery as primary treatment. Several questions regarding the effects, timing, methods and eligibility for primary surgery have yet to be answered. Robust evidence, which is anticipated from other ongoing trials examining surgery for metastatic breast cancer, is eagerly awaited.",
keywords = "Prognosis, Stage IV breast cancer, Surgery",
author = "Tadahiko Shien and Hiroji Iwata",
year = "2017",
month = "5",
day = "1",
doi = "10.1093/jjco/hyx027",
language = "English",
volume = "47",
pages = "381--384",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Significance of primary lesion resection in Stage IV breast cancer

AU - Shien, Tadahiko

AU - Iwata, Hiroji

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Primary breast tumor resection is not recommended with metastatic disease due to lack of evidence indicating prognostic benefit. Results from ongoing trials are needed to test tumor resection efficacy.Abstract: Systemic treatment with drugs is administered to prolong survival and palliate symptoms in Stage IV breast cancer patients who have distant metastases at diagnosis. Surgical procedures for the primary tumor are not actively recommended in guidelines due to lack of evidence indicating prognostic benefit. Recently, several retrospective studies have shown primary tumor resection to prolong overall survival in patients with Stage IV breast cancer. Prospective randomized trials began enrolling patients to examine this possibility and two have already reported results. However, the results of these two trials were discordant. The first trial, conducted in India, reported negative effects of primary tumor resection after primary systemic therapy. A Turkish trial then obtained a positive effect of surgery as primary treatment. Several questions regarding the effects, timing, methods and eligibility for primary surgery have yet to be answered. Robust evidence, which is anticipated from other ongoing trials examining surgery for metastatic breast cancer, is eagerly awaited.

AB - Primary breast tumor resection is not recommended with metastatic disease due to lack of evidence indicating prognostic benefit. Results from ongoing trials are needed to test tumor resection efficacy.Abstract: Systemic treatment with drugs is administered to prolong survival and palliate symptoms in Stage IV breast cancer patients who have distant metastases at diagnosis. Surgical procedures for the primary tumor are not actively recommended in guidelines due to lack of evidence indicating prognostic benefit. Recently, several retrospective studies have shown primary tumor resection to prolong overall survival in patients with Stage IV breast cancer. Prospective randomized trials began enrolling patients to examine this possibility and two have already reported results. However, the results of these two trials were discordant. The first trial, conducted in India, reported negative effects of primary tumor resection after primary systemic therapy. A Turkish trial then obtained a positive effect of surgery as primary treatment. Several questions regarding the effects, timing, methods and eligibility for primary surgery have yet to be answered. Robust evidence, which is anticipated from other ongoing trials examining surgery for metastatic breast cancer, is eagerly awaited.

KW - Prognosis

KW - Stage IV breast cancer

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85027104785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027104785&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx027

DO - 10.1093/jjco/hyx027

M3 - Review article

VL - 47

SP - 381

EP - 384

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

M1 - hyx027

ER -